Search Results - "Hovanky, Vanna"

Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment by Sidana, Surbhi, Peres, Lauren C, Hashmi, Hamza, Hosoya, Hitomi, Ferreri, Christopher, Khouri, Jack, Dima, Danai, Atrash, Shebli, Voorhees, Peter, Simmons, Gary, Sborov, Douglas W, Kalariya, Nilesh, Hovanky, Vanna, Bharadwaj, Sushma, Miklos, David, Wagner, Charlotte, Kocoglu, Mehmet H, Kaur, Gurbakhash, Davis, James A, Midha, Shonali, Janakiram, Murali, Freeman, Ciara, Alsina, Melissa, Locke, Frederick, Gonzalez, Rebecca, Lin, Yi, McGuirk, Joseph, Afrough, Aimaz, Shune, Leyla, Patel, Krina K, Hansen, Doris K

“…We evaluated patients with relapsed multiple myeloma with renal impairment (RI) treated with standard of care idecabtagene vicleucel (ide-cel), as outcomes…”
Get full text

Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma by Sidana, Surbhi, Hosoya, Hitomi, Jensen, Alexandria, Liu, Lawrence, Goyal, Anmol, Hovanky, Vanna, Sahaf, Bita, Bharadwaj, Sushma, Latchford, Theresa, Arai, Sally, Leahy, Sheryl, Mei, Matthew, Budde, Lihua E., Muffly, Lori S., Frank, Matthew J., Dahiya, Saurabh, Htut, Myo, Miklos, David, Janakiram, Murali

Get full text

160 Circulating tumor DNA for measurable residual disease (MRD) detection in multiple myeloma patients undergoing CAR T-cell therapy by Hosoya, Hitomi, Carleton, Mia, Tanaka, Kailee, Sworder, Brian, Hovanky, Vanna, Duran, George, Zhang, Tian, Khodadoust, Michael, Miklos, David, Arai, Sally, Iberri, David, Liedtke, Michaela, Sidana, Surbhi, Kurtz, David

“…BackgroundMeasurable residual disease (MRD) is an important predictor of survival outcomes in both newly diagnosed and relapsed/refractory multiple myeloma…”
Get full text

Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA by Hosoya, Hitomi, Carleton, Mia, Tanaka, Kailee L, Sworder, Brian, Hovanky, Vanna, Duran, George E, Zhang, Tian Y., Khodadoust, Michael S., Miklos, David B., Arai, Sally, Iberri, David, Liedtke, Michaela, Sidana, Surbhi, Kurtz, David M.

Get full text

Fludarabine Lymphodepletion Exposure Is Associated with Idecabtagene Vicleucel Toxicity in Relapsed and Refractory Multiple Myeloma Patients: Real-World Experience from the US Myeloma Immunotherapy Consortium by Wagner, Charlotte B, Sweiss, Karen, Anto, Eric, Gonzalez, Rebecca, Castaneda Puglianini, Omar Alexis, Freeman, Ciara Louise L., Ionescu, Filip, Patel, Krina K., Ferreri, Christopher, Gaballa, Mahmoud, Shune, Leyla, McGuirk, Joseph P, Sidana, Surbhi, Hovanky, Vanna, Khouri, Jack, Dima, Danai, Hashmi, Hamza, Davis, James A, Afrough, Aimaz, Kaur, Gurbakhash, Anderson, Larry D., Forsberg, Peter A., Herr, Megan, Hansen, Doris K., Sborov, Douglas, Kocoglu, Mehmet H.

“…Background. Idecabtagene vicleucel (ide-cel) is an anti-B-cell maturation antigen (BCMA) CAR-T associated with durable responses in relapsed/refractory…”
Get full text

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma by Sidana, Surbhi, Patel, Krina K, Peres, Lauren C, Bansal, Radhika, Kocoglu, Mehmet Hakan, Shune, Leyla, Atrash, Shebli, Smith, Kinaya, Midha, Shonali, Ferreri, Christopher J, Dhakal, Binod, Dima, Danai, Costello, Patrick, Wagner, Charlotte, Reshef, Ran, Hosoya, Hitomi, Mikkilineni, Lekha, Atanackovic, Djordje, Chhabra, Saurabh, Parrondo, Ricardo D, Nadeem, Omar, Mann, Hashim, Kalariya, Nilesh, Hovanky, Vanna, DeAvila, Gabriel, Freeman, Ciara L, Locke, Frederick L, Alsina, Melissa, Wong, Sandy, Herr, Megan M, Htut, Myo, McGuirk, Joseph P, Sborov, Douglas W, Khouri, Jack, Martin, Thomas, Janakiram, Murali, Lin, Yi, Hansen, Doris K

“…Ciltacabtagene autoleucel (cilta-cel) CAR-T therapy was approved in 2022 for patients with relapsed/refractory multiple myeloma (RRMM). We report outcomes with…”
Get full text

Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience by Khouri, Jack, Li, Hong, Hansen, Doris K., Sidana, Surbhi, Shune, Leyla O., DeJarnette, Shaun, Anwer, Faiz, Sborov, Douglas W, Wagner, Charlotte B, Kocoglu, M. Hakan, Atrash, Shebli, Voorhees, Peter M., Valent, Jason, Peres, Lauren C., Hovanky, Vanna, Simmons, Gary, Dima, Danai, Kalariya, Nilesh, Afrough, Aimaz, Kaur, Gurbakhash, Sannareddy, Aishwarya, Ferreri, Christopher J., Davis, James, McGuirk, Joseph P., Locke, Frederick L., Baz, Rachid C., Hamilton, Betty K., Alsina, Melissa, Sauter, Craig S., Hashmi, Hamza, Patel, Krina

Get full text

Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience by Sidana, Surbhi, Peres, Lauren C., Hashmi, Hamza, Hosoya, Hitomi, Ferreri, Christopher J., Atrash, Shebli, Khouri, Jack, Voorhees, Peter M., Dima, Danai, Simmons, Gary, Kalariya, Nilesh, Hovanky, Vanna, Bharadwaj, Sushma, Arai, Sally, Miklos, David B., Wagner, Charlotte B, Davis, James, Sborov, Douglas W., Nishihori, Taiga, Alsina, Melissa, Locke, Frederick L., Gonzalez, Rebecca, Kocoglu, M. Hakan, Sannareddy, Aishwarya, Afrough, Aimaz, McGuirk, Joseph P., Shune, Leyla O., Patel, Krina, Hansen, Doris K.

Get full text

Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma by Logue, Jennifer M., Peres, Lauren C., Hashmi, Hamza, Colin-Leitzinger, Christelle M., Shrewsbury, Alexandria M., Hosoya, Hitomi, Gonzalez, Rebecca M., Copponex, Christina, Kottra, Krista H., Hovanky, Vanna, Sahaf, Bita, Patil, Sunita, Lazaryan, Aleksandr, Jain, Michael D., Baluch, Aliyah, Klinkova, Olga V., Bejanyan, Nelli, Faramand, Rawan G., Elmariah, Hany, Khimani, Farhad, Davila, Marco L., Mishra, Asmita, Blue, Brandon J., Grajales-Cruz, Ariel F., Castaneda Puglianini, Omar A., Liu, Hien D., Nishihori, Taiga, Freeman, Ciara L., Brayer, Jason B., Shain, Kenneth H., Baz, Rachid C., Locke, Frederick L., Alsina, Melissa, Sidana, Surbhi, Hansen, Doris K.

“…•Grade ≥ 3 cytopenias were at their worst at day 7 after ide-cel (94% of patients) but persisted in 40% at day 90, particularly thrombocytopenia.•Infections…”
Get full text

Immune Reconstitution and Infectious Complications Following BCMA-Targeted CAR-T Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) by Moscvin, Maria, Goyal, Anmol, Jensen, Alexandria, Epstein, Dr. David J, Hovanky, Vanna, Mikkilineni, Lekha, Bennett, Leslie, Latchford, Theresa M., Arai, Sally, Bharadwaj, Sushma, Frank, Matthew J., Dahiya, Saurabh, Muffly, Lori S, Miklos, David B., Hosoya, Hitomi, Sidana, Surbhi

“…Although BCMA-targeted CAR-T therapy has demonstrated efficacy in RRMM, prolonged immunosuppression and infectious complications result in significant…”
Get full text

Clinical outcomes after idecabtagene vicleucel in older patients with multiple myeloma: a multicenter real-world experience by Kalariya, Nilesh M., Hildebrandt, Michelle A. T., Hansen, Doris K., Sidana, Surbhi, Khouri, Jack, Ferreri, Christopher J., Doyle, William N., Castaneda-Puglianini, Omar, Freeman, Ciara L., Hovanky, Vanna, Hosoya, Hitomi, Shune, Leyla O., Patel, Krina K.

“…•The safety and efficacy benefits of ide-cel were proportionate in young and older patients despite frailty and geriatric characteristics.•Treatment with…”
Get full text

Abstract 5707: Tumor and immune determinants of response to anti-BCMA CAR T-cell therapy in multiple myeloma using cell-free DNA by Carleton, Mia, Hosoya, Hitomi, Tanaka, Kailee L., Sworder, Brian, Hovanky, Vanna, Sahaf, Bita, Frank, Matthew J., Duran, George E., Zhang, Tian Y., Arai, Sally, Iberri, David, Liedtke, Michaela, Miklos, David B., Khodadoust, Michael S., Sidana, Surbhi, Kurtz, David M.

“…Abstract Background: Multiple myeloma (MM) is an incurable disease with a heterogenous clinical course and genomic landscape. Autologous anti-BCMA chimeric…”
Get full text

Circulating Tumor DNA for Disease Characterization and Response Prediction in Myeloma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy by Hosoya, Hitomi, Carleton, Mia, Tanaka, Kailee, Sworder, Brian, Hovanky, Vanna, Duran, George E, Zhang, Tian Y, Khodadoust, Michael, Miklos, David B., Arai, Sally, Iberri, David, Liedtke, Michaela, Sidana, Surbhi, Kurtz, David

Get full text

1 - Circulating Tumor DNA for Disease Characterization and Response Prediction in Myeloma Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy by Hosoya, Hitomi, Carleton, Mia, Tanaka, Kailee, Sworder, Brian, Hovanky, Vanna, Duran, George E, Zhang, Tian Y, Khodadoust, Michael, Miklos, David B., Arai, Sally, Iberri, David, Liedtke, Michaela, Sidana, Surbhi, Kurtz, David

Get full text

Idecabtagene Vicleucel (ide-cel) Chimeric Antigen Receptor T-Cell for Plasma Cell Leukemia (PCL): A Multicenter Experience by Fortuna, Gliceida Maria Galarza, Sidana, Surbhi, Hovanky, Vanna, Khouri, Jack, Dima, Danai, Kocoglu, Mehmet H., Forsberg, Peter, Ferreri, Christopher, Atrash, Shebli, Voorhees, Peter M., Hashmi, Hamza, Davis, James, Gaballa, Mahmoud, Anto, Eric, De Avila, Gabe, Peres, Lauren, Patel, Krina K., Hansen, Doris K, Sborov, Douglas

“…Despite improvements in long-term outcomes of patients (pts) with multiple myeloma, the prognosis of pts with plasma cell leukemia (PCL) remains poor. We…”
Get full text

Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience by Khouri, Jack, Dima, Danai, Li, Hong, Hansen, Doris, Sidana, Surbhi, Shune, Leyla, Anwer, Faiz, Sborov, Douglas, Wagner, Charlotte, Kocoglu, Mehmet H., Atrash, Shebli, Voorhees, Peter, Peres, Lauren, Hovanky, Vanna, Simmons, Gary, Williams, Louis, Raza, Shahzad, Afrough, Aimaz, Anderson, Larry D., Ferreri, Christopher, Hashmi, Hamza, Davis, James, McGuirk, Joseph, Goldsmith, Scott, Borogovac, Azra, Lin, Yi, Midha, Shonali, Nadeem, Omar, Locke, Frederick L., Baz, Rachid, Hamilton, Betty, Alsina, Melissa, Sauter, Craig, Patel, Krina, Kaur, Gurbakhash

“…•We explored the impact of ALC on the survival outcomes of myeloma patients treated with commercial idecabtagene vicleucel.•We created a new ALC profile and…”
Get full text

42 - Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) with Renal Impairment: Real World Experience by Sidana, Surbhi, Peres, Lauren, Hashmi, Hamza, Hosoya, Hitomi, Ferreri, Christopher, Atrash, Shebli, Khouri, Jack, Voorhees, Peter M., Dima, Danai, Simmons, Gary Lee, Kalariya, Nilesh, Hovanky, Vanna, Bharadwaj, Sushma, Arai, Sally, Miklos, David B., Wagner, Charlotte, Davis, James, Sborov, Douglas, Nishihori, Taiga, Alsina, Melissa, Locke, Frederick L., Gonzalez, Rebecca, Kocoglu, Mehmet H., Sannareddy, Aishwarya, Afrough, Aimaz, McGuirk, Joseph P., Shune, Leyla, Patel, Krina K., Hansen, Doris K

Get full text

Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) with Renal Impairment: Real World Experience by Sidana, Surbhi, Peres, Lauren, Hashmi, Hamza, Hosoya, Hitomi, Ferreri, Christopher, Atrash, Shebli, Khouri, Jack, Voorhees, Peter M., Dima, Danai, Simmons, Gary Lee, Kalariya, Nilesh, Hovanky, Vanna, Bharadwaj, Sushma, Arai, Sally, Miklos, David B., Wagner, Charlotte, Davis, James, Sborov, Douglas, Nishihori, Taiga, Alsina, Melissa, Locke, Frederick L., Gonzalez, Rebecca, Kocoglu, Mehmet H., Sannareddy, Aishwarya, Afrough, Aimaz, McGuirk, Joseph P., Shune, Leyla, Patel, Krina K., Hansen, Doris K

Get full text